Loading the company…
Loading the company…
In the last ten years FDA made 0 decisions for Lensar (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family. The latest was on 2012-12-03.
| Family | Decisions on record |
|---|---|
| Cataract & MIGS | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2012-12-03 | 510(k) | K122829 | LENSAR LASER SYSTEM - FS 3D FOR CORNEAL INCISIONS |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Lensar.
In 2025, Lensar reported engagement with 319 surgeons and other clinicians in the states MedaRep covers, worth $615K in consulting, speaking, meals and travel for its device products, the most in Colorado ($235K to 11). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Colorado ($235K, 11 engaged), Florida ($105K, 32 engaged), Texas ($74K, 51 engaged), California ($55K, 20 engaged), Pennsylvania ($40K, 6 engaged).